生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | Ticlopidine Hydrochloride is a hydrochloride form of Ticlopidine. Ticlopidine is a selective and the first FDA-approved P2Y12 antagonist which can affect platelet aggregation when. It can be metabolized through cytochrome P450 in the liver and forms the active thienopyridine metabolites. The thienopyridine metabolites can irreversibly antagonize the P2Y12 receptor[3]. This results in inhibition of the binding of the P2Y12 agonist 2-methylthio-ADP and the ADP-induced downregulation of adenylyl cyclase[4]. |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT01381185 | Acute Myocardial Infarction | Phase 4 | Completed | - | Czech Republic ... 展开 >> University Hospital Ostrava Ostrava, Poruba, Czech Republic, 70852 Departement of Laboratory Medicine, Prostejov Hospital Prostejov, Czech Republic, 79604 收起 << |
NCT01448330 | Healthy | Phase 1 | Completed | - | Korea, Republic of ... 展开 >> Samsung medical center Seoul, Korea, Republic of 收起 << |
NCT01469416 | Healthy | Phase 1 | Completed | - | United States, California ... 展开 >> Clinical Research Center, UCSF San Francisco, California, United States, 94143 收起 << |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.33mL 0.67mL 0.33mL |
16.65mL 3.33mL 1.67mL |
33.31mL 6.66mL 3.33mL |
参考文献 |
---|